Phase 2 Breast Cancer Trial, Recruiting NCT07537699 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT07537699
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 85 years old
  • People who have had a full surgical removal of the breast (radical mastectomy) and need follow-up chemotherapy using a combination of two drugs called docetaxel and cyclophosphamide
  • People who are generally able to carry out daily activities, rated on a standard scale from 0 (fully active) to 2 (up and about more than half of the day) — (confirm with trial site)
  • People whose blood counts are within an acceptable range, including platelets, white blood cells, and a type of white blood cell called neutrophils
  • People whose liver function blood test results are within acceptable limits — specifically, bilirubin no more than 1.5 times the normal upper limit, and liver enzymes no more than 5 times the normal upper limit
  • People with no fluid build-up in the abdomen, no blockage in the digestive system, normal blood clotting, and a blood protein (albumin) level of at least 30g/L
  • People whose liver is functioning well enough to be rated "Grade A" on a standard liver health scoring system called Child-Pugh
  • People whose kidneys are working well, based on a blood test for creatinine or a calculated measure of how well the kidneys filter waste — (confirm with trial site)

Who may not be able to join:

  • People who have inflammation or infection in or around the outer ear
  • People who have a tendency to bleed easily or have blood clotting problems
  • People with severe fluid build-up in the abdomen
  • People with a blockage in the digestive system
  • People experiencing a severe spike in blood pressure or blood pressure affecting the brain
  • People with serious uncontrolled health conditions such as active infection or uncontrolled diabetes
  • People who have had a stroke or heart attack in the six months before joining, or who have poorly controlled high blood pressure, unstable chest pain, heart failure, or a heart rhythm problem requiring medication
  • People with central nervous system conditions such as a primary brain tumour, epilepsy not controlled by standard treatment, any history of cancer spreading to the brain, or a history of stroke
  • People who have had a serious allergic reaction to any of the drugs used in this trial
  • People who are pregnant or breastfeeding
  • People with other diseases, complications from cancer spread, or concerning findings on physical examination that may make the study drugs unsafe for them
  • People who are unable or unwilling to follow the requirements of the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 June 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
25 November 2025
Est. completion
1 November 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Proportion of patients experiencing nausea as assessed by NIC-CTC AE4.0

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov